Drug Database · Clinicians

Tobramycin

Brands (43) Mycinidin, Tobidina, Tobra-V…Show all

Aminoglycoside Antibacterial US FDA class
Antibacterial (aminoglycoside); Anti-infective; and others PH FDA category

Eye use: no kidney adjustmentRx · Prescription drug51 PH productsPNF-listedPhilHealth GAMOT Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 5b66bba3-cf97-4a9c-b618-ba5f277f20f6, version date October 26, 2026 (TOBREX · Novartis Pharmaceuticals Corporation). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE TOBREX ® (tobramycin ophthalmic ointment) 0.3 % is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria.
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE TOBREX ® (tobramycin ophthalmic ointment) 0.3 % is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of TOBREX (tobramycin ophthalmic ointment) 0.3%. Clinical studies have shown tobramycin to be safe and effective for use in children.

Contraindications

  • Hypersensitivity to any component
renalcarematters.com, reviewed
Contraindications (US label) US FDA label

CONTRAINDICATIONS TOBREX (tobramycin ophthalmic ointment) 0.3 % is contraindicated in patients with known hypersensitivity to any of its components.

Dosing: Adult

  • External eye infections (ointment): Mild to moderate: half-inch ribbon 2 or 3 times daily. Severe: every 3 to 4 hours until improvement, then taper (label)
renalcarematters.com, reviewed
Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION In mild to moderate disease, apply a half-inch ribbon into the affected eye(s) 2 or 3 times per day. In severe infections, instill a half-inch ribbon into the affected eye(s) every 3 to 4 hours until improvement, following which treatment should be reduced prior to discontinuation. How to Apply TOBREX (tobramycin ophthalmic ointment) 0.3%: 1.

Tilt your head back. 2. Place a finger on your cheek just under your eye and gently pull down until a ''V'' pocket is formed between your eyeball and your lower lid. 3. Place a small amount (about ½ inch) of TOBREX ® (tobramycin ophthalmic ointment) 0.3% in the ''V'' pocket. Do not let the tip of the tube touch your eye. 4.

Look downward before closing your eye.

Dosing: Altered kidney function

All tobramycin products registered in the Philippines are 0.3% eye drops or eye ointment. The ophthalmic label gives the same dose for everyone and no kidney adjustment. Injectable tobramycin, an aminoglycoside that needs kidney dosing and level monitoring, is not registered in the Philippine list and is not covered here.

Kidney function measure: Not applicable (topical ophthalmic product).

Show full dosing details
CrCl ≥60 mL/min
Eye drops or ointment: same dose at any kidney function; the label gives no kidney adjustment (topical use).
CrCl 30–59 mL/min
Eye drops or ointment: same dose at any kidney function; the label gives no kidney adjustment (topical use).
CrCl 15–29 mL/min
Eye drops or ointment: same dose at any kidney function; the label gives no kidney adjustment (topical use).
CrCl <15 mL/min (not on dialysis)
Eye drops or ointment: same dose at any kidney function; the label gives no kidney adjustment (topical use).
Hemodialysis (intermittent)
Eye drops or ointment: same dose at any kidney function; the label gives no kidney adjustment (topical use).
Peritoneal dialysis
Eye drops or ointment: same dose at any kidney function; the label gives no kidney adjustment (topical use).
CRRT
Eye drops or ointment: same dose at any kidney function; the label gives no kidney adjustment (topical use).
  • Dialyzable? Not relevant for ophthalmic use.
  • Monitoring Clinical response of the eye infection; hypersensitivity. The label notes nephrotoxicity and ototoxicity with systemic aminoglycosides, not with eye use.
Children (kidney dosing)
Show full dosing details
eGFR ≥60
Eye use: no kidney adjustment (label).
eGFR 30–59
Eye use: no kidney adjustment (label).
eGFR 15–29
Eye use: no kidney adjustment (label).
eGFR <15 (not on dialysis)
Eye use: no kidney adjustment (label).
Hemodialysis (intermittent)
Eye use: no kidney adjustment.
Peritoneal dialysis
Eye use: no kidney adjustment.
CRRT
Eye use: no kidney adjustment.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

Dosing: Pediatric

Approved ages
Safe and effective in children (label indications); not established under 2 months (label 8.4).
Usual dose
Same as adults.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed
Pediatric use (US label) US FDA label

Pediatric Use: Safety and effectiveness in pediatric patients below the age of 2 months has not been established.

Dosing: Older adult

Geriatric use (US label) US FDA label

Geriatric Use: No overall clinical differences in safety or effectiveness have been observed between the elderly and other adult patients.

Dosage forms

Philippines

  • Ophthalmic solution: 3 mg/mL
  • Sterile ophthalmic solution: 3 mg/mL
  • Ophthalmic ointment: 3 mg/g
  • Sterile ophthalmic ointment: 3 mg/g
  • Ophthalmic drops solution: 3 mg/mL
  • Per gram sterile opthalmic ointment: 3 mg

Registered products in the Philippines

51 products registered with the Food and Drug Administration (FDA) Philippines list Tobramycin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products51
Philippine FDA-registered products for Tobramycin
Package insert
AccetobTobramycin
3 mg/mL (0.3% w/v) Ophthalmic Solution (Eye Drops)White HDPE bottle x 5 mL and 10 mL (net content) with white HDPE nozzle and cap (Box of 1's)
Rx
Opal Laboratories (Pvt.) LimitedPakistan
Accesspoint International Trading Inc.Importer: Accesspoint International Trading, Inc.
DRP-15471
Jul 16, 2029
AdtredTobramycin
3 mg/mL (0.3% w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE white opaque plastic droptainer in 5 mL (net content) (Box of 1’s)
Rx
Egyptian International Pharmaceutical Industries Co. (EIPIPCO)Egypt
Sensomed Phil., Inc.Importer: Ambica International Corporation
DRP-8044-08
Dec 5, 2028
AguacinTobramycin Sulfate
0.3% w/v Ophthalmic Solution5 mL HDPE Bottle with dropper tip and pilfer-proof cap (Box of 1's)
Rx
Bharat Parenteral LimitedIndia
Greencore Pharma Inc.Importer: SRS Life Sciences
DRP-1577-01
Aug 3, 2027
AguatobTobramycin (as sulfate)
3 mg/mL (0.3% w/v) Ophthalmic Solution (Drops)5 mL and 10 mL HDPE Dropper Bottle (Box of 1's)
Rx
Scott-Edil Pharmacia LimitedIndia
Agua Visions TradingImporter: Greencore Pharma Inc.
DRP-13606-01
Mar 16, 2028
CinarexTobramycin
3 mg/mL (0.3% w/v) Ophthalmic Solution (Eye Drops)Opaque (white) Low Density Polyethylene Bottle with white High Density Polyethylene Screw Cap and White LDPE Dropper x 5 mL (net content). (Box of 1's)
Rx
Beximco Pharmaceuticals LtdBangladesh
Aglobal Care, Inc.
DRP-10089
Aug 13, 2029
CONSACTobramycin
3 mg/mL (0.3% w/v) Ophthalmic SolutionLDPE Plastic Dropper-Tipped Bottle x 5mL Box of 1's
Rx
Ashford Pharmaceutical Laboratories, Inc.Philippines
Trader: Medilife Pharma, Inc.
DRP-1012
Mar 8, 2030
IkshatobTobramycin
3 mg/mL (0.3% w/v) Ophthalmic Solution (Drops)LDPE Plastic Bottle with Green Cap x 6 mL (Box of 1's)
Rx
Daewoo Pharm. Co., Ltd.Republic of Korea
Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corp.
DRP-8138-03
Oct 31, 2029
MaxitobraTobramycin
3 mg/mL (0.3% w/v) Ophthalmic Solution (Drops)LDPE Plastic Bottle with Green Cap x 6 mL (Box of 1's)
Rx
Daewoo Pharm. Co., Ltd.Republic of Korea
Qure Corp.Importer: Bliss Pharma Distribution and Consultancy Corp.
DRP-8138-02
Oct 31, 2029
MycinidinTobramycin
3 mg/ mL (0.3 % w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE white opaque plastic droptainer in 5 mL (net content) (Box of 1's)
Rx
Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt
Medchoice Vision Care Inc.Importer: Ambica International Corporation
DRP-8044-01
Dec 5, 2028
MycinidinTobramycin
3 mg/mL (0.3% w/v) Ophthalmic Solution (Drops)LDPE Plastic Bottle with green cap x 6 mL (Box of 1's)
Rx
Daewoo Pharm. Co., Ltd.Republic of Korea
Medchoice Vision Care Inc.Importer: Bliss Pharma Distribution and Consultancy Corp.
DRP-8138-05
Oct 31, 2029
MytocinTobramycin
3 mg/mL Sterile Ophthalmic SolutionLDPE Dropper tipped bottle x 5 mL Box of 1's
Rx
Ashford Pharmaceutical Laboratories, Inc.Philippines
Trader: Vendiz Pharmaceuticals Inc.
DRP-2182
Nov 11, 2029
NebraTobramycin
3mg/mL (0.3%) Sterile Ophthalmic Solution10 mL LDPE Bottle x 5mL Box of 1's
Rx
Remington Pharmaceutical Industries (Pvt.) Ltd.Pakistan
Ophthamed Pharma Corp.
DRP-12264
Jun 16, 2031
NeoconTobramycin
3 mg/mL (0.3%) Ophthalmic SolutionLDPE Plastic Dropper-Tipped Bottle x 5 mL (Box of 1's)
Rx
Ashford Pharmaceutical Laboratories, Inc.Philippines
Pharmabiz Solutions, Inc.Trader: Medilife Pharma, Inc.
DRP-1012-03
Mar 8, 2030
NoneTobramycin
3 mg/ mL (0.3% w/v) Ophthalmic Solution (Eye Drops)HDPE Bottle x 5mL (Box of 1's)
Rx
e. L Laboratories, Inc.Philippines
Trader: Celsus Pharmaceuticals Phils., Inc.
DR-XY30560
Feb 16, 2030
NONETobramycin
3 mg/mL (0.3 % w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE white opaque plastic droptainer in 5 mL (net content) (Box of 1's)
Rx
Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt
PharmaVital Corp.Importer: Ambica International Corporation
DRP-8044-10
Dec 5, 2028
NoneTobramycin
3 mg/mL (0.3% w/v) Ophthalmic SolutionLDPE Plastic Dropper-Tipped Bottle x 5 mL Box of 1's
Rx
Ashford Pharmaceutical Laboratories, Inc.Philippines
Celsus Pharmaceuticals Phils., Inc.Trader: Medilife Pharma, Inc.
DRP-1012-04
Mar 8, 2030
NovamycinTobramycin (as sulfate)
3 mg/mL (0.3% w/v) Ophthalmic Solution (Eye Drops).White LDPE Bottle Sealed with HDPE Cap x 15 mL (Box of 1's)
Rx
Pharmacos Exakta, S.A. De C.VMexico
Medinova Pharmaceutical, Inc.,
DRP-12481
Mar 3, 2028
ObramicinTobramycin
3 mg/mL (0.3% w/v) Ophthalmic Solution (Eye Drops)White Opaque LDPE Bottle Sealed with HDPE Cap and White LDPE Dropper x 5 mL (Box of 1's)
Rx
World Medicine İlaç Sanayi Ve Ticaret A.Ş.Turkey
Orange Biotec, Inc.
DRP-14459
Sep 7, 2028
OcusynTobramycin
3 mg/mL (0.3 % w/v Sterile Ophthalmic Solution (Eye Drops)LDPE White Plastic dropper tip bottle and HDPE cap x 5 mL (Box of 1's)
Rx
Laboratorios Ashford Lda.China
Marrion Pharma, Inc.
DRP-6030
Oct 3, 2030
OphthamycinTobramycin
3 mg/ mL (0.3% w/v) Ophthalmic Solution (Drops)5 mL LDPE Bottle (Box of 1's)
Rx
Samchundang Pharm Co., Ltd.Republic of Korea
Starpharm, Inc.
DRP-15489
Aug 18, 2031
OptobTobramycin
3 mg/mL (0.3% w/v) Ophthalmic Solution (Drops)LDPE Plastic Bottle with green cap x 6 mL Box of 1's
Rx
DAEWOO PHARM. CO., LTD.Republic of Korea
Afree Pharmaceutical Distribution Corp.Importer: Bliss Pharma Distribution and Consultancy Corporation
DRP-8138-01
Oct 31, 2029
RamitobTobramycin
3 mg/mL (0.3% w/v) Ophthalmic Solution (Drops)LDPE Plastic Bottle with green cap x 6 mL (Box of 1's)
Rx
Daewoo Pharm. Co., Ltd.Republic of Korea
Bliss Pharma Distribution and Consultancy Corp.
DRP-8138
Oct 31, 2029
RaytobraxTobramycin
3 mg/mL (0.3 % w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE White Opaque Plastic Droptainer in 5 mL (net content) Box of 1's
Rx
Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt
RCL Ophthalmic SurgicalsImporter: Ambica International Corporation
DRP-8044-02
Dec 5, 2028
RetobracynTobramycin
3 mg / mL (0.3% w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE white opaque plastic droptainer in 5 mL (net content) [Box of 1’s]
Rx
Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt
Reta DrugImporter: Ambica International Corporation
DRP-8044-07
Dec 5, 2028
Retobracyn-RTobramycin
3 mg / mL (0.3% w/v) Ophthalmic Solution (Eye Drops)White HDPE bottle x 5 mL and 10 mL (net content) with white HDPE nozzle and cap (Box of 1's)
Rx
Opal Laboratories (Pvt.) LimitedPakistan
Reta DrugImporter: Accesspoint International Trading Inc.
DRP-15471-02
Jul 16, 2029
T-MycinTobramycin
3 mg/mL (0.3% w/v) Ophthalmic Solution (Eye Drops)5 mL White Opaque LDPE Plastic Dropper Bottle (Box of 1's)
Rx
Aristopharma Ltd.Bangladesh
Sahar International Trading Inc.
DRP-7729
Mar 27, 2027
Tobcin EyeTobramycin (as sulfate)
3 mg/mL (0.3% w/v) Ophthalmic Solution5 mL white LDPE vial with HDPE cap and nozzle (Box of 1's)
Rx
East African (India) OverseasIndia
Airlife International Trading Corporation.Importer: Airlife International Trading Corporation
DRP-16121
Nov 6, 2029
TobiclearTobramycin
3 mg/mL (0.3% w/v) Ophthalmic Solution (Drops)LDPE Plastic Bottle with green cap x 6 mL (Box of 1's)
Rx
Daewoo Pharm. Co., Ltd.Republic of Korea
TGP Phama Inc.Importer: Bliss Pharma Distribution and Consultancy Corp.
DRP-8138-04
Oct 31, 2029
TobidinaTobramycin (as Sulfate)
3 mg/g (0.3% w/w) Ophthalmic OintmentAluminum tube x 5 g (Box of 1's)
Rx
Indiana OphthalmicsIndia
Aglobal Care Inc.Importer: Aglobal Care, Inc.
DRP-13479
Feb 27, 2028
TobidinaTobramycin (as sulfate)
3 mg/mL (0.3% w/v) Ophthalmic Solution5 mL sterile opaque plastic bottle with nozzle and cap (Box of 1's)
Rx
Indiana Ophthalmics.India
Aglobal Care, Inc.
DRP-15875
Sep 25, 2029
Tobra-VTobramycin
3 mg/g (0.3% w/w) Ophthalmic OintmentAluminum collapsible tube x 3.5 g (Box of 1's)
Rx
Ashford Pharmaceutical Laboratories, Inc.Philippines
Trader: Vista Pharma, Inc.
DR-XY35176
Sep 12, 2027
Tobra-VTobramycin
3 mg/mL (0.3% w/v) Sterile Ophthalmic Solution10 mL LDPE/HDPE Plastic Eye Dropper x 5 mL (Box of 1's)
Rx
El Laboratories, Inc.Philippines
Trader: Vista Pharma, Inc.
DR-XY33010
Nov 26, 2027
TobracareTobramycin
3 mg / mL (0.3% w/v) Ophthalmic Solution (Eye Drops)White HDPE bottle x 5 mL (net content) with white HDPE nozzle and cap (Box of 1's)
Rx
Opal Laboratories (Pvt.) LimitedPakistan
Savelink Pharma and Trading Co.Importer: Accesspoint International Trading Inc.
DRP-15471-01
Jul 16, 2029
TobracidTobramycin (as sulfate)
3mg/mL (0.3% w/v) Ophthalmic Solution (Eye Drops)LDPE Bottle with Translucent LDPE Nozzle Sealed with White Cap x 5 mL (Box of 1's)
Rx
Makcur Laboratories LimitedIndia
Ensight Pharmaceuticals Inc.Trader: Entod Pharmaceuticals Ltd.
DR-XY49458
Jul 31, 2030
TobracorTobramycin
3 mg / mL (0.3 % w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE white opaque plastic droptainer in 5 mL (net content) (Box of 1's)
Rx
Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-8044-05
Dec 5, 2028
TobragoTobramycin
3 mg/mL (0.3 % w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE white opaque plastic droptainer in 5 mL (net content) Box of 1's
Rx
Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt
Applied Pharmaceutical Distribution IncImporter: Ambica International Corporation
DRP-8044-03
Dec 5, 2028
TobrakhrizTobramycin (as sulfate)
3mg/mL (0.3% w/v) Ophthalmic Drops Solution (Eye Drops)PP Dropper Botlte with cap x 5 mL (Box of 1's)
Rx
Merit Organics LimitedIndia
Khriz Pharma Trading, Inc.
DR-XY49717
May 13, 2031
TobralcinTobramycin Sulfate
0.3% w/v Ophthalmic Solution
Rx
Bharat Parenterals Limited
SRS Life Sciences Inc.
DRP-1577
Aug 3, 2027
TobraloupeTobramycin (as sulfate)
3 mg/mL (0.3 % w/v) Ophthalmic Solution (Drops)5 mL HDPE Dropper Bottle (Box of 1's)
Rx
Scott-Edil Pharmacia LimitedIndia
PNJ Pharma EnterpriseImporter: Greencore Pharma Inc.
DRP-13606-02
Mar 16, 2028
TobralyfTobramycin
3 mg/mL (0.3 % w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE white opaque plastic droptainer in 5 mL (net content) (Box of 1's)
Rx
Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation
DRP-8044-04
Dec 5, 2028
TobranovTobramycin
3 mg/mL (0.3% w/v) Ophthalmic Solution
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant III Injectables)India
Medinova Pharmaceutical Inc.Trader: Unosource Pharma Ltd.
DRP-17603
Feb 20, 2031
TobrasafeTobramycin
3 mg/mL (0.3% w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE white opaque plastic droptainer in 5 mL (net content) (Box of 1’s)
Rx
Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt
Preventia Healthcare Inc.Importer: Ambica International Corporation
DRP-8044-06
Dec 5, 2028
TobrasaphTobramycin (as sulfate)
3 mg/mL (0.3% w/v) Ophthalmic Solution (Drops)5 mL White HDPE Dropper Bottle and Single Pilfer Proof Ring Cap (Box of 1's)
Rx
Kilitch Drugs (India) Ltd.India
Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-13181
Dec 16, 2027
TobraxaTobramycin Sulfate
3mg/mL (0.3% w/v)LDPE Plastic Bottle x 5mL (Box of 1's)
Rx
Axa Parenterals Ltd.India
Brady Pharma Inc.
DRP-9895
Jun 24, 2031
TobrazinTobramycin Sulfate
3 mg/mL (0.3% w/v) Ophthalmic Solution (Drops)5 mL and 10 mL HDPE Dropper Bottle (Box of 1's)
Rx
Scott-Edil Pharmacia LimitedIndia
Greencore Pharma Inc.
DRP-13606
Mar 16, 2028
TobrexTobramycin
3 mg/g (0.3%) Sterile Ophthalmic OintmentAluminum Ophthalmic Tube x 3.5 g (Box of 1's)
Rx
Siegfried El Masnou, S.A.Spain
Importer: Novartis Healthcare Philippines, Inc.
DR-XY39418
May 9, 2031
TobrexTobramycin
3 mg/mL (0.3% w/v) Sterile Ophthalmic Solution (Eye Drops)Plastic droptainer x 5 mL (Box of 1's)
Rx
Alcon-Couvreur NVBelgium
Importer: Novartis Healthcare Philippines, Inc.
DR-XY7060
Oct 25, 2029
TobrinTobramycin
3 mg/g (0.3% w/w) Sterile Ophthalmic Ointment.Collapsible Aluminum Tube x 5 g (Box of 1 tube)
Rx
Egyptian International Pharmaceutical Industries Co.Egypt
Ambica International Corporation
DRP-15064
Apr 2, 2029
TobrinTobramycin
3 mg/mL (0.3 % w/v) Sterile Ophthalmic Solution (Eye Drops)LDPE white opaque plastic droptainer in 5 mL (net content) Box of 1's
Rx
Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt
Ambica International Corporation
DRP-8044
Dec 5, 2028
TomracinTobramycin
3 mg/mL (0.3%) Sterile Ophthalmic Solution (Drops)5 mL LDPE Bottle (Box of 1's)
Rx
EBE PHARMACEUTICAL CO., LTD.China
AGLOBAL CARE, INC.
DRP-6646
Jan 22, 2030
ZartobTobramycin (as sulfate)
3 mg per gram (0.3 % w/w) Sterile Opthalmic OintmentAluminum collapsible tube with plastic cap x 5 g (Box of 1's)
Rx
Indiana OphthalmicsIndia
Ophtha Pharma Traders Inc.Importer: Medinova Pharmaceutical Inc.
DRP-13471-01
Feb 27, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS NOT FOR INJECTION INTO THE EYE. Sensitivity to topically applied aminoglycosides may occur in some patients. Severity of hypersensitivity reactions may vary from local effects to generalized reactions such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions. If a sensitivity reaction to TOBREX (tobramycin ophthalmic ointment) 0.3% occurs, discontinue use.

Adverse reactions

Common

  • Local eye reactions: lid itching and swelling, conjunctival redness (under 3%)

Serious

  • Hypersensitivity, including anaphylaxis; Stevens-Johnson syndrome, erythema multiforme (postmarketing)
renalcarematters.com, reviewed
Adverse reactions (US label) US FDA label

ADVERSE REACTIONS: The most frequent adverse reactions to TOBREX (tobramycin ophthalmic ointment) 0.3% are hypersensitivity and localized ocular toxicity, including lid itching and swelling, and conjunctival erythema. These reactions occur in less than three of 100 patients treated with TOBREX ® (tobramycin ophthalmic ointment) 0.3%.

Postmarketing Experience: Additional adverse reactions identified from postmarketing use include anaphylactic reaction, Stevens-Johnson syndrome, and erythema multiforme. The following additional adverse reactions have been reported with systemic aminoglycosides: Neurotoxicity, ototoxicity and nephrotoxicity have occurred in patients receiving systemic aminoglycoside therapy.

Aminoglycosides may aggravate muscle weakness in patients with known or suspected neuromuscular disorders, such as myasthenia gravis or Parkinson’s disease, because of their potential effect on neuromuscular function.

Monitoring parameters

  • Clinical response of the eye infection; hypersensitivity. The label notes nephrotoxicity and ototoxicity with systemic aminoglycosides, not with eye use. Kidney
  • Clinical response; signs of sensitivity
renalcarematters.com, reviewed

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy: Reproduction studies in three types of animals at doses up to thirty-three times the normal human systemic dose have revealed no evidence of impaired fertility or harm to the fetus due to tobramycin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers: Because of the potential for adverse reactions in nursing infants from TOBREX ® (tobramycin ophthalmic ointment) 0.3%, a decision should be made whether to discontinue nursing the infant or discontinue the drug, taking into account the importance of the drug to the mother.

Pharmacokinetics

Key PK parameters

Dialyzability kidneyNot relevant (ophthalmic)
renalcarematters.com, reviewed
Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY In Vitro Data: In vitro studies have demonstrated tobramycin is active against susceptible strains of the following microorganisms: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae.

Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. Bacterial susceptibility studies demonstrate that in some cases, microorganisms resistant to gentamicin retain susceptibility to tobramycin.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Tobramycin Eye Drops 0.3%, 5 mL Bottle₱70.00–₱206.39Reference ₱160.00per bottleDPRI procurement range
Tobramycin Eye Ointment 0.3%, 3.5 g Tube₱192.40–₱453.33Reference ₱192.40per tubeDPRI procurement range
0.3% ophthalmic drop solution in 5 mL bottle₱345.00per bottlePhilHealth GAMOT fixed fee
0.3% ophthalmic ointment in 3.5 g tube₱519.50per tubePhilHealth GAMOT fixed fee

PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Tobramycin
PNF listingEye Drops Solution: 0.3%, 5 mL bottle
PNF listingEye Ointment: 0.3%, 3.5 g tube
PhilHealth GAMOTYes (listed since July 28, 2025)

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. TOBREX · Novartis Pharmaceuticals Corporation [US FDA-approved label, version 7, October 26, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b66bba3-cf97-4a9c-b618-ba5f277f20f6
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  5. PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  6. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
  7. Novartis Pharmaceuticals Corporation. (2026). TOBREX (tobramycin ophthalmic ointment) 0.3% [Prescribing information; US FDA-approved label, NDA050555, set ID 5b66bba3-cf97-4a9c-b618-ba5f277f20f6, version effective October 26, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b66bba3-cf97-4a9c-b618-ba5f277f20f6

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .